GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway

Abstract

Abstract:ObjectiveTo explore the mechanism of glycine dehydrogenase (GLDC) regulating the proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway.MethodsRNA interference method was used to silence the expression of GLDC in ovarian cancer cell lines HEY and SK-OV-3. The HEY and SK-OV-3 cells were divided into si-control group (transfected with siRNA-control), si-GLDC#1 group (trans-fected with siRNA-GLDC#1) and si-GLDC#2 group (transfected with siRNA-GLDC#2). The expression level of GLDC and the protein phosphorylation level of PI3K/Akt/mTOR were detected by Western blotting. Cell proli-feration, migration and apoptosis were detected by CCK-8 method, Transwell chamber test, cell scratch test and flow cytometry.ResultsThe relative expression levels of GLDC in the si-control group, si-GLDC#1 group amd si-GLDC#2 group of HEY cells were 1.00±0.01, 0.68±0.10, 0.80±0.08, and there was a statistically significant difference (F=13.80,P=0.006). The relative expression levels of GLDC in the si-control group, si-GLDC#1 group and si-GLDC#2 group of SK-OV-3 cells were 1.02±0.01, 0.58±0.17, 0.60±0.25, and there was a statistically significant difference (F=6.08,P=0.036). The absorbance (A) values in the si-control group, si-GLDC#1 group and si-GLDC#2 group of HEY cells were 1.04±0.03, 0.91±0.02, 0.82±0.01 at 24 h after transfection, 1.53±0.13, 1.30±0.03, 1.29±0.07 at 48 h after transfection, 1.44±0.08, 1.25±0.01, 1.15±0.03 at 72 h after transfection, and there were statistically significant differences (F=83.14,P<0.001;F=8.96,P=0.007;F=29.55,P<0.001). Further pairwise comparison showed that the proliferation abilities of the si-GLDC#1 and si-GLDC#2 group at 24, 48 and 72 h were significantly lower than those of the si-control group (allP<0.05). In HEY cells, the migration numbers of cells in the si-control group, si-GLDC#1 group and si-GLDC#2 group were 57.33±6.43, 27.67±5.13 and 30.67±2.31, and there was a statistically significantly difference (F=32.88,P=0.001). The migration numbers of cells in the si-GLDC#1 group and si-GLDC#2 group were significantly lower than that in the si-control group (P<0.001; P=0.001). Similar results were also observed in SK-OV-3 cells. In SK-OV-3 cells, the scratch healing rates in the si-control group, si-GLDC#1 group and si-GLDC#2 group were (51.27±1.59)%, (26.35±2.94)% and (26.34±7.69)%, and there was a statistically significant difference (F=26.54, P=0.001). The scratch healing rates in the si-GLDC#1 group and si-GLDC#2 group were significantly lower than that in the si-control group (bothP=0.001). In HEY cells, the apoptosis rates in the si-control group, si-GLDC#1 group and si-GLDC#2 group were (7.11±0.82)%, (10.44±1.50)%, (17.39±1.55)%, and there was a statistically significantly difference (F=46.52,P<0.001). The apoptosis rates in the si-GLDC#1 group and si-GLDC#2 group were significantly higher than that in the si-control group (P=0.022;P<0.001). Similar results were also observed in SK-OV-3 cells. In HEY cells, there was no significant difference in total PI3K protein in the si-control group, si-GLDC#1 group and si-GLDC#2 group (F=0.54,P=0.631), but there were significant differences in pAkt/Akt and pmTOR/mTOR levels (F=22.14,P=0.016;F=10.57,P=0.044). The pAkt/Akt and pmTOR/mTOR levels in the si-GLDC#1 group and si-GLDC#2 group were significantly lower than those in the si-control group (P=0.015,P=0.008;P=0.039,P=0.023). Similar results were also observed in SK-OV-3 cells.ConclusionIn ovarian cancer cells, GLDC silencing can inhibit cell proliferation and promote apoptosis by inhibiting the PI3K/Akt/mTOR pathway.

Key words:Ovarian neoplasms,Cell proliferation,Cell movement,Cell apoptosis,Glycine dehydrogenase

Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao. GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway[J]. Journal of International Oncology, 2021, 48(12): 716-722.

Figures/Tables5

组别	0 h	24 h	48 h	72 h
si-control组	0.52±0.02	1.04±0.03	1.53±0.13	1.44±0.08
si-GLDC#1组	0.52±0.02	0.91±0.02^a	1.30±0.03^b	1.25±0.01^d
si-GLDC#2组	0.49±0.03	0.82±0.01^a	1.29±0.07^c	1.15±0.03^a
F值	1.64	83.14	8.96	29.55
P值	0.247	<0.001	0.007	<0.001

组别	HEY		SK-OV-3
si-control组	1.00±0.01	1.19±0.16	1.00±0.06	0.71±0.09	0.94±0.09	1.01±0.09
si-GLDC#1组	1.30±0.39	0.71±0.01^a	0.52±0.16^a	0.93±0.01	0.50±0.17^a	0.62±0.01^a
si-GLDC#2组	1.14±0.31	0.59±0.05^a	0.41±0.16^a	0.71±0.29	0.50±0.06^a	0.50±0.11^a
F值	0.54	22.14	10.57	0.97	9.67	21.14
P值	0.631	0.016	0.044	0.475	0.049	0.017

References13

[1]	Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(4):284-296. DOI: 10.3322/caac.21456.
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021,71(1):7-33. DOI: 10.3322/caac.21654.
[3]	Kikuchi G. The glycine cleavage system: composition, reaction mechanism, and physiological significance[J]. Mol Cell Biochem, 1973,1(2):169-187. DOI: 10.1007/bf01659328.
[4]	Leung KY, Pai YJ, Chen Q, et al. Partitioning of one-carbon units in folate and methionine metabolism is essential for neural tube closure[J]. Cell Rep, 2017,21(7):1795-1808. DOI: 10.1016/j.celrep.2017.10.072.
[5]	Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumo-rigenesis[J]. Cell, 2012,148(1-2):259-272. DOI: 10.1016/j.cell.2011.11.050.
[6]	Zhuang H, Wu F, Wei W, et al. Glycine decarboxylase induces autophagy and is downregulated by miRNA-30d-5p in hepatocellular carcinoma[J]. Cell Death Dis, 2019,10(3):192. DOI: 10.1038/s41419-019-1446-z.
[7]	Rice MS, Rist PM, Winter AC, et al. Migraine and invasive epithelial ovarian cancer risk in the nurses' health study Ⅱ and the women's health study[J]. Int J Cancer, 2018,142(3):534-539. DOI: 10.1002/ijc.31062.
[8]	Kim D, Fiske BP, Birsoy K, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance[J]. Nature, 2015,520(7547):363-367. DOI: 10.1038/nature14363.
[9]	Li N, Li H, Cao L, et al. Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas[J]. Endocr Relat Cancer, 2018,25(10):909-931. DOI: 10.1530/ERC-18-0243.
[10]	Zhuang H, Li Q, Zhang X, et al. Downregulation of glycine decarboxylase enhanced cofilin-mediated migration in hepatocellular carcinoma cells[J]. Free Radic Biol Med, 2018,120:1-12. DOI: 10.1016/j.freeradbiomed.2018.03.003.
[11]	Chen Y, Gu D, Wen Y, et al. Identifying the novel key genes in renal cell carcinoma by bioinformatics analysis and cell experiments[J]. Cancer Cell Int, 2020,20:331. DOI: 10.1186/s12935-020-01405-6.
[12]	Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth[J]. Oncogene, 2004,23(34):5853-5857. DOI: 10.1038/sj.onc.1207721.
[13]	Wang CY, Chiao CC, Phan NN, et al. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer[J]. Am J Cancer Res, 2020,10(1):95-113.

[1]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136.
[2]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[3]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[4]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[5]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[6]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[7]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[8]	Lian Haiwei, Yang Shuorui, Liu Renzhong.Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326.
[9]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198.
[10]	Shi Yu, Chen Xi, Xu Mengqi, Zhang Yingying, Ji Honghai, Jiang Yingying.Effects of PSIP1 gene silencing on migration and invasion of oral squamous cell carcinoma cells[J]. Journal of International Oncology, 2022, 49(3): 129-133.
[11]	Laibijiang Wusiman, Cao Bowei, Zhang Wenbin, Gao Hua.Effects of exogenous AGR2 on the proliferation and invasion abilities of colon cancer cells[J]. Journal of International Oncology, 2022, 49(2): 73-78.
[12]	Zhang Yongli, Zhang Ruojia, Fan Huancai, Ge Luna, Wang Lin.TXNDC5-Prx2 axis regulates drug resistance of prostate cancer cells[J]. Journal of International Oncology, 2021, 48(8): 473-478.
[13]	Jiang Mengting, Wang Jiachun, Zong Jing.Effects of NFAT5 inhibition on proliferation, invasion, migration and apoptosis of lung adenocarcinoma cells[J]. Journal of International Oncology, 2021, 48(6): 321-327.
[14]	Yan Xingyu, Lian Zhenying, Diao Yutao, Liu Hongyan.BMXΔN mediates gefitinib resistance of lung cancer cells through ERK/MAPK signaling pathway[J]. Journal of International Oncology, 2021, 48(6): 328-334.
[15]	Wang Ziyi, Chen Hongjie, Yang Ninggang, Zhang Jun, Zhang Xiangjun, Yu Xinning, Ma Zhongyi, Dai Enlai.Effects of decorin on proliferation, migration and invasion of bladder cancer cells[J]. Journal of International Oncology, 2021, 48(6): 335-340.